Skip to content
PICO Portalanswers from OpenAlex

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

PaperCitations, authors & open-access status

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma is a paper indexed in PICO Portal from OpenAlex.

How many citations does Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma have?

PICO Portalcitation count

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma has 417 citations in the OpenAlex counts PICO Portal stores.

When was Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma published?

PICO Portalyear

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma has 2021 year in the PICO Portal index.

What is the open-access status of Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma?

PICO Portaloa status

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma has gold oa status in the PICO Portal index.

What is the DOI of Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma?

PICO Portaldoi

The DOI for Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma is on the source record.

What is the PMID of Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma?

PICO Portalpmid

The PMID for Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma is on the source record.

What is the OpenAlex record for Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma?

PICO Portalopenalex

The OpenAlex for Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial